EBNA1BP2

Across TCGA pan-cancer cohorts, EBNA1BP2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated EBNA1BP2 data layer compared with 27 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher EBNA1BP2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated EBNA1BP2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, READ, and PRAD are the cancer types where EBNA1BP2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	III,IV	0.098	0.728	<.001	24	view →
READ	OS	Median	III,IV	0.328	0.751	.003	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LIHC	OS	Median	All	0.255	0.773	.012	6	view →
UCEC	DFS	Median	All	1.000	0.831	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

EBNA1BP2–HNSC (OS)

Open the HNSC breakdown →